Prestige (PBH) Q1 Revenue Falls 6.6%
Prestige Consumer Healthcare (NYSE:PBH), the over-the-counter (OTC) healthcare product company behind brands such as Clear Eyes, Monistat, and Chloraseptic, released its first-quarter results for fiscal 2026 on August 7, 2025. The most vital news was that GAAP revenue and earnings per share both fell short of expectations, mainly due to supply constraints in its North American Eye Ear Care business and some orders that were accelerated into Q4 FY2025. Revenue (GAAP) was $249.5 million, below the analyst estimate of $266.9 million (GAAP) and down 6.6% from the prior year period. Non-GAAP diluted earnings per share (EPS) came in at $0.95, missing the GAAP EPS estimate of $1.04 but Non-GAAP diluted EPS increased 5.6% from $0.90 in Q1 FY2025 to $0.95 in Q1 FY2026. Overall, the quarter reflected both persistent challenges in certain product lines and positives such as improved margin and higher non-GAAP free cash flow.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q4 2025 earnings report.
Prestige Consumer Healthcare (NYSE:PBH) is a leading provider of branded OTC healthcare products. Its portfolio includes well-known remedies across categories such as eye care (Clear Eyes), feminine care (Monistat, Summer’s Eve), sore throat relief (Chloraseptic), and wart removal (Compound W). These brands enjoy high market recognition, with 61.5% of annual revenue in FY2025 coming from products that held top market positions in their respective categories.
Source Fool.com
